Researchers at Baylor College of Medicine and Rice University have received a $2.3 million Breakthrough Award from the ...
The phase 1/2 study will assess next-generation immunotherapy alone and in combination with an immune checkpoint inhibitor in ...
A phase 2 study for patients with HR-positive, HER2-negative metastatic breast cancer will be evaluating alisertib plus ...
Elacestrant, a selective estrogen receptor degrader, demonstrated significant improvements in progression-free survival (PFS) ...
Linda D’Addario, a cancer survivor, now mentors others through Cancer Hope Network, a program now available at five area ...
GlobalData on MSN1d
Novartis and Olema expand alliance with $250m to boost breast cancer trialsOlema Oncology plans to start a Phase III trial studying palazestrant with a CDK4/6 inhibitor from Novartis in mid-2025.
Barbara O’Brien, MD, discusses the next steps of the phase 2 TBCRC049 study for the treatment of patients with HER2-positive ...
A study from researchers at the University of Michigan and the University of California San Diego has shed light on a ...
On Nature published the results of an innovative breast cancer research project from the Netherlands. This study, the SONIA ...
The Data Safety Monitoring Board (DSMB) stated no safety concerns, and recommended continuation of BriaCell’s pivotal Phase 3 study of Bria-IMT™ ...
The "Metastatic Triple-Negative Breast Cancer (mTNBC)- Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.This report provides comprehensive insights about 10+ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback